| 0.5802 0.073 (14.44%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.05  |
1-year : | 6.22 |
| Resists | First : | 3.46 |
Second : | 5.32 |
| Pivot price | 0.59 |
|||
| Supports | First : | 0.46 | Second : | 0.38 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.6 |
| MA(100) : | 3.43 |
MA(250) : | 2.75 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 20.1 |
D(3) : | 13.9 |
| RSI | RSI(14): 25.6 |
|||
| 52-week | High : | 7.19 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CALC ] has closed below upper band by 46.5%. Bollinger Bands are 86.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.68 | 0.68 - 0.69 |
| Low: | 0.55 - 0.56 | 0.56 - 0.56 |
| Close: | 0.6 - 0.6 | 0.6 - 0.61 |
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Tue, 03 Mar 2026
CalciMedica (NASDAQ: CALC) files shelf to offer up to $125M in securities - Stock Titan
Tue, 03 Mar 2026
CalciMedica (NASDAQ: CALC) outlines Auxora pipeline, halted AKI trial and going concern risk - Stock Titan
Tue, 03 Mar 2026
CalciMedica (Nasdaq: CALC) widens 2025 loss while advancing Auxora and PAH candidate - Stock Titan
Tue, 03 Mar 2026
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates - PR Newswire
Sat, 28 Feb 2026
CALC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fri, 30 Jan 2026
How Is The Market Feeling About CalciMedica Inc? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 23.6 (%) |
| Held by Institutions | 47.5 (%) |
| Shares Short | 700 (K) |
| Shares Short P.Month | 80 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -100.1 % |
| Return on Equity (ttm) | -526.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.38 |
| PEG Ratio | 0 |
| Price to Book value | -30.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|